Search
Now showing items 1-1 of 1
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance
(2012)
OSI-930, a dual c-Kit and KDR tyrosine kinase inhibitor, is reported to have undergone a Phase I dose escalation study in patients with advanced solid tumors. A series of fifteen pyridyl and phenyl analogues of OSI-930 ...